Reports

Stephan Emmerth

Stephan Emmerth

PhD | Director Therapeutic Innovation and BaseLaunch


Tel. +41 61 295 50 17

stephan.notexisting@nodomain.comemmerth@baselarea.notexisting@nodomain.comswiss
report Life Sciences
(img: mosquitoe/pixabay)

(img: mosquitoe/pixabay)

11.09.2017

Evolva awarded contract from U.S. government

The ingredient manufacturer Evolva has been awarded a contract by the U.S. government to develop a new form of protection against insects in an effort to combat mosquito-borne diseases like Zika.

The contract from the Centers for Disease Control and Prevention (CDC) is worth $8.35 million and will run for 18 months, according to an Evolva statement. The Basel-based ingredient manufacturer will develop the insect protection on the basis of its ingredient nootkatone, which is derived from citrus fruits. Nootkatone can be produced in a sustainable, industrial-scale process by means of yeast fermentation.

Evolva and CDC have been collaborating for some time on the use of nootkatone against a wide variety of biting pests. It was originally tested for use against ticks that carry Lyme disease, but a goal in the future is to also have it effectively prevent the transmission of mosquito-borne diseases.

Evolva is pursuing a strategy to advance market-safe, sustainably produced products. Alongside stevia and resveratrol, nootkatone is one of the its main ingredients or substances. The contract with the U.S. government supports this strategy, explains Evolva.

Categories

Life Sciences
Cookies

BaselArea.swiss uses cookies to ensure you get the best service on our website.
By continuing to browse the site, you are agreeing to the use of cookies.

Ok